HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long-acting β-agonists in asthma management: what is the current status?

Abstract
Large surveillance studies or phase IV clinical studies of long-acting β-agonists (LABA) compared with placebo in asthma patients using variable (from nil to regular) doses of inhaled corticosteroids (ICS) have raised the issue of mortality risk in patients with asthma taking regular LABA. There have been a number of meta-analyses and systematic reviews that have examined the risk of LABA in asthma patients, and the general conclusion is that LABA added to ICS reduces asthma-related hospitalizations compared with ICS alone and there is no statistical increase in mortality. However, LABA without ICS do increase mortality risk in asthma. All reviews and analyses show a greater number of LABA deaths, but not all are statistically significant. A recent meta-analysis found LABA with concomitant ICS had a higher mortality rate in asthma than ICS alone. The flaw in the study is the higher doses of ICS in the control arms, but the implicit message remains: the essential need for enough ICS to control airway inflammation. We suggest that the pragmatic solution is to have LABA only available in the same device as ICS for asthma treatment. We do not think that a study comparing the safety of LABA plus ICS versus ICS alone in asthma is necessary. If such a study is conducted, the measurement of morbidity from increased doses of ICS is an essential design consideration. Furthermore, the critical focus in asthma management should not be forgotten - education of health professionals and the community of the critical role of ICS, and the need for good communication between health professionals and the asthma patient to facilitate good asthma control. The same arguments apply to the asthma-with-chronic obstructive pulmonary disease overlap syndrome in older patients. There is an urgent need to provide medical practitioners with the capability to diagnose the overlap syndrome.
AuthorsSatya Mysore, Richard E Ruffin
JournalDrugs (Drugs) Vol. 71 Issue 16 Pg. 2091-7 (Nov 12 2011) ISSN: 1179-1950 [Electronic] New Zealand
PMID22035511 (Publication Type: Journal Article)
Chemical References
  • Adrenal Cortex Hormones
  • Adrenergic beta-Agonists
  • Anti-Asthmatic Agents
  • Delayed-Action Preparations
  • Ethanolamines
  • Salmeterol Xinafoate
  • Albuterol
  • Formoterol Fumarate
Topics
  • Administration, Inhalation
  • Adrenal Cortex Hormones (administration & dosage, adverse effects)
  • Adrenergic beta-Agonists (therapeutic use)
  • Albuterol (analogs & derivatives, therapeutic use)
  • Anti-Asthmatic Agents (therapeutic use)
  • Asthma (drug therapy)
  • Delayed-Action Preparations
  • Drug Therapy, Combination
  • Ethanolamines (therapeutic use)
  • Formoterol Fumarate
  • Humans
  • Meta-Analysis as Topic
  • Pulmonary Disease, Chronic Obstructive (drug therapy)
  • Randomized Controlled Trials as Topic
  • Salmeterol Xinafoate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: